| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Clozapine | Clozapine EP Impurity A | VL1310001 | View CAS 50892-62-1 |
| Clozapine | Clozapine EP Impurity B | VL1310002 | View CAS 263366-81-0 |
| Clozapine | Clozapine EP Impurity C | VL1310003 | View CAS 6104-71-8 |
| Clozapine | Clozapine EP Impurity D | VL1310004 | View CAS 65514-71-8 |
| Clozapine | Clozapine N-Oxide Impurity | VE006464 | View CAS 34233-69-7 |
| Clozapine | 2, 8-Dichloro-6, 12-diphenyldibenzo[b, f][1, 5]diazocine | VE008750 | View CAS 3646-61-5 |
| Catalogue No. | VL1310002 |
| CAS No. | 263366-81-0 |
| Molecular Formula | C30H24Cl2N6 |
| Molecular Weight | 539.46 |
| Parent drug | Clozapine |
| IUPAC Name | 1, 4-bis(8-chloro-5H-dibenzo[b, e][1, 4]diazepin-11-yl)piperazine |
| Synonyms | Clozapine BP Impurity B |
| References | Aravagiri, M., and S. R. Marder. “Simultaneous Determination of Clozapine and Its N-Desmethyl and N-Oxide Metabolites in Plasma by Liquid Chromatography/Electrospray Tandem Mass Spectrometry and Its Application to Plasma Level Monitoring in Schizophrenic Patients.” Journal of Pharmaceutical and Biomedical Analysis, vol. 26, no. 2, Sept. 2001, pp. 301–11, https://doi.org/10.1016/s0731-7085(01)00410-1.? Wagstaff, Antona J., and Harriet M. Bryson. “Clozapine.” CNS Drugs, vol. 4, no. 5, Nov. 1995, pp |
| Status | In-stock |
| ListName | Clozapine EP Impurity B |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
